Monitor the separate special meeting filing for the Scancell merger, which will contain material terms and voting requirements. The proxy's explicit separation of the merger from this annual meeting suggests the deal timeline extends beyond November 2, 2026.
Price Chart
Executive Summary
Neuphoria Therapeutics Inc. filed its definitive proxy statement for the 2026 Annual Meeting of Stockholders to be held on November 2, 2026. The meeting agenda includes the election of one Class II director (Alan Fisher), ratification of Wolf & Company P.C. as independent auditor, and authorization of meeting adjournment if needed. The filing explicitly notes that it does not cover the proposed merger with Scancell Holdings plc announced on July 23, 2026, which will be addressed at a separate special meeting. The proxy is routine with no shareholder proposals, contested elections, or material governance changes.
Key Facts
- Annual Meeting scheduled for November 2, 2026, virtual-only format
- Only one director up for election: incumbent Alan Fisher (Class II, age 73)
- Board consists of 5 members with classified staggered terms
- No shareholder proposals on the ballot
- Proxy statement explicitly excludes the proposed Scancell Holdings plc merger
- 5,411,334 shares of common stock outstanding as of record date September 10, 2026
- Lynx1 Capital Management LP beneficially owns 16.2% of outstanding shares
- CEO Spyridon Papapetropoulos transitioned to interim CEO under a consulting agreement effective January 1, 2026, after his employment terminated December 31, 2025
- FY2026 total compensation for former CEO Papapetropoulos was $1,674,690, including $1,117,740 in severance and other compensation
- CFO Tim Cunningham's services are provided through Danforth Advisors LLC; total payments to Danforth were $843,714 in FY2026
- Audit fees paid to Wolf & Company P.C. were $323,500 for FY2026 and $258,000 for FY2025
- Director David Wilson's firm WG Partners LLP received $219,981 in fees during FY2026 for financial advisory services related to strategic alternatives
Financial Impact
Routine proxy filing with no direct financial impact. CEO severance of $1,117,740 and CFO consulting fees of $325,894 are disclosed but already accrued.
Risk Factors
- Proposed Scancell merger is subject to shareholder approvals from both companies and other closing conditions
- CEO transition to interim status and consulting arrangement creates leadership uncertainty
- 16.2% holder Lynx1 Capital Management could influence voting outcomes
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEF 14A Filing (Primary) | 0001140361-26-037139 |
| Document: 0001140361-26-037139-index-headers.html | 0001140361-26-037139 |
| Document: 0001140361-26-037139-index.html | 0001140361-26-037139 |
| Document: 0001140361-26-037139.txt | 0001140361-26-037139 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 4d ago | 8-K | $3.44 | awaiting T+60 | — | $3.38 (−1.74%) |
Oct 5, 2026 22d ago | SC 13G | $3.45 | awaiting T+60 | — | $3.38 (−2.03%) |
Sep 18, 2026 5w ago | DEFA14A | $3.71 | awaiting T+60 | — | $3.38 (−8.89%) |
Sep 18, 2026 5w ago | DEFA14A | $3.71 | awaiting T+60 | — | $3.38 (−8.89%) |
Sep 18, 2026 5w ago | DEF 14A | $3.71 | awaiting T+60 | — | $3.38 (−8.89%) |
Jun 26, 2026 17w ago | Press Release | $4.40 $3.74 | ▼ −15.11% | ▼ −19.50% | $3.38 (−23.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers